Fecal microbiota transplantation is an effective treatment for Clostridium difficile infection
Fecal microbiota transplantation is widely supported by clinical literature, systematic reviews, and professional guidelines as a highly effective and established treatment for recurrent Clostridium difficile infection.
All relevant retrieved papers consistently agree that fecal microbiota transplantation is an effective, established treatment for recurrent Clostridioides difficile infection, with high cure rates and inclusion in major clinical guidelines. There are no papers refuting this claim.
Weerakoon S, Avula S, Mandefro BT, Sundara SV, Lu X, Busmail H, Malasevskaia IA. Microbiota-Based Therapies for Recurrent Clostridium difficile Infection: A Systematic Review of Their Efficacy and Safety.. 2025. https://doi.org/10.7759/cureus.90737
A systematic review notes that FMT and standardized microbiome therapeutics demonstrate superior clinical cure rates compared to traditional therapies for recurrent Clostridioides difficile infection.
See more details
Bethlehem L, Bartu L, Marke G, Mar P, Feldman S, Eggers J, Ruprecht C, Britton GJ, Aggarwala V, Bongers G, Li Z, Yang N, Hohmann EL, Mogno I, Faith JJ, Grinspan A. 15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial.. 2026. https://doi.org/10.1038/s41591-026-04442-2
A randomized phase 1b trial demonstrates that fecal microbiota transplant effectively prevents recurrent Clostridioides difficile infection.
Miller CB, Bader GA, Kay CL. Fecal Microbiota Transplantation in 2025: Two Steps Forward, One Step Back.. 2026. https://doi.org/10.1007/s11894-025-01030-1
A review highlights that FMT has been integrated into routine algorithms and clinical guidelines for treating Clostridioides difficile infection following extensive supportive evidence and recent FDA approvals.
Zambelli G, Masetti M, Rasmi S, Addati I, Bonacorsi L, Diona S, Esposito S. Restoring Microbial Balance: Clinical Applications, Challenges, and Future Directions of Fecal Microbiota Transplantation in Pediatric Disorders.. 2026. https://doi.org/10.3390/microorganisms14061241
A pediatric review confirms that recurrent Clostridioides difficile infection is the primary and best-supported indication for FMT, with high success rates.
Zhao J, Fan Y, Yang K, Gao H. Fecal microbiota transplantation: from empirical remedy to precision medicine.. 2026. https://doi.org/10.3389/frmbi.2026.1863308
A review of FMT's evolution details its established and high efficacy in treating recurrent Clostridioides difficile infection.
Melchiorri S, Besutti VM, Castagliuolo I. Blastocystis spp. in fecal microbiota transplantation: Evidence, policy, and the screening paradox.. 2026. https://doi.org/10.1016/j.ijid.2026.108548
A study on donor screening notes that FMT remains an established and successful treatment for recurrent Clostridioides difficile infection despite specific donor parasite screening nuances.
Lin ML, Gao HN. Transplantation of encapsulated fecal microbiota: research progress and future trends.. 2026. https://doi.org/10.1007/s12519-026-01056-z
A review on encapsulated fecal microbiota confirms significant efficacy of FMT in treating intestinal disorders such as recurrent Clostridioides difficile infection.
Ryazanov V, Vershinina I, Inchagova K, Bukareva E, Kolpakov V, Ruchay A, Kosyan D, Marinchev M, Zdorov A. Fecal microbiota and microbial community transplantation: <b>a</b> review of current research.. 2026. https://doi.org/10.3389/fmicb.2026.1814047
A review of microbial community transplantation reiterates FMT's role as a successful treatment for Clostridioides difficile infection.
The paper trail · every fact has a biography
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work · Dispute this receipt